- Home
- AMPL vs NVCR Comparison
AMPL vs NVCR Comparison
Compare AMPL & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMPL | NVCR |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AMPL | NVCR |
|---|---|---|
| Price | $16.61 | $13.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | $15.36 | ★ $25.71 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.84 | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | $343,214,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $19.51 | $12.91 |
| Revenue Next Year | $15.89 | $9.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.68 | 8.28 |
| 52 Week Low | $5.51 | $9.82 |
| 52 Week High | $17.84 | $21.45 |
Technical Indicators
Market Signals| Indicator | AMPL | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 55.60 | 40.06 |
| Support Level | $6.05 | $11.73 |
| Resistance Level | $17.84 | $18.43 |
| Average True Range (ATR) | 0.93 | 0.81 |
| MACD | -0.15 | -0.03 |
| Stochastic Oscillator | 37.16 | 33.69 |
Price Performance
Historical ComparisonAbout AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue through selling subscriptions to the platform. The company derives a majority of its revenue from the United States, and also has its presence in Internationally.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.